Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zelira Therapeutics has the GF Score of 1, which implies that the company
might have
Worst future performance potential, or not enough data.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Zelira Therapeutics
might have
Worst future performance potential, or not enough data.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Zelira Therapeutics GF Score Related Terms
FRA:G1G vs MTNB, SXTP, GLMD: GF Score Comparison
For the Biotechnology subindustry, Zelira Therapeutics's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zelira Therapeutics GF Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zelira Therapeutics's GF Score distribution charts can be found below:
* The bar in red indicates where Zelira Therapeutics's GF Score falls into.
Zelira Therapeutics (FRA:G1G) has a GF Score of 1 as of Jul. 17, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Zelira Therapeutics and its competitors. This is 95% below median its historical median of 21.00. Over the past decade, Zelira Therapeutics' GF Score has ranged from 1.00 to 37.00.
Is Zelira Therapeutics' GF Score too high?
Zelira Therapeutics' current GF Score of 1 is 95% below median its 10-year median of 21.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 37.00. Overall, Zelira Therapeutics has a GF Score™ of 1/100, reflecting its overall financial health beyond just this single metric.
How does Zelira Therapeutics' GF Score compare to MTNB and SXTP?
Zelira Therapeutics' GF Score of 1 can be compared against companies in the Biotechnology industry. Historically, Zelira Therapeutics' own GF Score has ranged from 1.00 to 37.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Zelira Therapeutics and its competitors. Zelira Therapeutics's current GF Score is 1, which is 95% below median its own 10-year median of 21.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zelira Therapeutics stock overvalued right now?
Zelira Therapeutics (FRA:G1G) has a current GF Score of 1. The stock's GF Value™ is €0.07, compared to a current price of €0.30 — trading 328.6% above its estimated fair value. The current GF Score is 1, which is 95% below median its 10-year median of 21.00. Zelira Therapeutics' overall GF Score™ is 1/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Zelira Therapeutics (FRA:G1G), the current GF Score is 1 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zelira Therapeutics (FRA:G1G) Overvalued in 2026?
Based on GuruFocus' analysis, Zelira Therapeutics stock appears to be overvalued.
The current stock price of €0.30 is trading 328.6% above its estimated GF Value™ of €0.07.
Key valuation signals for FRA:G1G:
GF Score: 1 (95% below median its 10-year median of 21.00)
GF Value™: €0.07 vs. price of €0.30 (328.6% above fair value)
No single metric tells the full story. See the FRA:G1G stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema, and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer. The company is organised into two operating segments based on geographic location of operations: Australia and United States of America.
1GF Score
Get the complete analysis for FRA:G1G
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:G1G has been successfully added to your 
